Skip to main content
. 1999 Sep;37(9):2781–2788. doi: 10.1128/jcm.37.9.2781-2788.1999

TABLE 2.

Typing, susceptibility, and mupA analysis results of CoNS isolates

Isolate no. Isolation date (day.mo.yr) Source of isolationa Mupirocin MIC (μg/ml) REAP pattern PFGE pattern RAPD pattern mupA PCR result mupA locus polymorph Resistanceb
S. epidermidis
 BNM 8 23.11.1993 e 32 C1 b C/C PT
 BNM 51 9.6.1994 c 64 C1 b C/C EP
 BNM 2 4.8.1993 e 64 C2 b C/C EPT
 BNM 9 23.11.1993 e 128 C2 b C/C EPT
 BNM 19 12.1.1994 i 64 C2 b C/C EPT
 BNM 20 2.2.1994 i 32 C2 b C/C EPT
 BNM 21 31.1.1994 e 32 C2 b C/C EPT
 BNM 16 4.1.1994 e 5,120 C3 b C/C + I EKPT
 BNM 27 1.4.1994 i 5,120 C3 b C/C + I EPT
 BNM 37 4.5.1994 e 4,096 C4 b C/C + I EPT
 BNM 44 7.6.1994 c 4,096 D1 b C/C + II PT
 BNM 54 24.6.1994 c 4,096 D1 b C/C + II EPT
 BNM 23 28.2.1994 e 1,024 D2 b C/C + II EGPSX
 BNM 61 21.6.1994 c 8,192 E d G/C + I GKPST
 BNM 18 4.1.1994 e 4,096 F h B/B + I EPT
 BNM 22 28.02.94 e 2,048 F h B/B + I EPT
 BNM 29 12.04.94 e 2,048 G1 h B/B + I EPT
 BNM 35 24.04.94 i 4,096 G1 h B/B + I EPT
 BNM 11 16.12.93 i 4,096 G2 h B/B + I EPT
 BNM 56 21.06.94 c 4,096 H1 h B/B + I EPT
 BNM 52 20.06.94 c 4,096 H2 h B/C + I EP
 BNM 42 6.06.94 e 2,048 I f1 F/C + II AGKPT
 BNM 59 20.06.94 c 4,096 I f1 F/C + II GKPST
 BNM 43 6.06.94 e 4,096 J f2 F/C + II GKPTX
 BNM 48 8.06.94 c 4,096 J f1 F/C + II GKPTX
 BNM 57 20.06.94 c 4,096 K f3 F/E + I GKPT
 BNM 5 16.11.93 i 4,096 B2 c H/B + I KP
 BNM 65 24.06.94 c 4,096 B2 c H/B + I KP
 BNM 67 30.05.94 e 4,096 B2 c H/B + I KP
 BNM 36 6.05.94 i 4,096 L g D/C + I KPT
 BNM 40 4.05.94 e 4,096 M e E/D + I AGKP
S. xylosus BNM 4 20.10.93 c 4,096 N j I/F III
S. haemolyticus BNM 33 26.04.94 i 8,192 O i G/J + I EGKPS
S. capitis BNM 64 22.06.94 c 2,048 P k C/H + I P
a

Isolation sources: i, site of infection; e, environment; c, carriers. 

b

Explanation of resistance patterns: A, amikacin resistance; E, erythromycin resistance; G, gentamicin resistance; K, kanamycin resistance; P, penicillin resistance; S, streptomycin resistance; T, tetracycline resistance; X, trimethoprim-sulfamethoxazole resistance.